KR20240040092A - 섬유모세포 활성화 단백질 억제제 및 그의 용도 - Google Patents

섬유모세포 활성화 단백질 억제제 및 그의 용도 Download PDF

Info

Publication number
KR20240040092A
KR20240040092A KR1020247005694A KR20247005694A KR20240040092A KR 20240040092 A KR20240040092 A KR 20240040092A KR 1020247005694 A KR1020247005694 A KR 1020247005694A KR 20247005694 A KR20247005694 A KR 20247005694A KR 20240040092 A KR20240040092 A KR 20240040092A
Authority
KR
South Korea
Prior art keywords
compound
group
nos
tumor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247005694A
Other languages
English (en)
Korean (ko)
Inventor
프란크 오스테르캄프
디르크 츠보랄스키
마티아즈 파쉬케
아일린 회네
예시카 바스네르-테쉬네르
크리스티안 하제
율리히 라이네케
크리스티안 스메르링
얀 운게비쓰
안네 브레덴베크
크리스토프 깁슨
외른 소위페
Original Assignee
쓰리비 파마슈티컬스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쓰리비 파마슈티컬스 게엠베하 filed Critical 쓰리비 파마슈티컬스 게엠베하
Publication of KR20240040092A publication Critical patent/KR20240040092A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247005694A 2021-07-23 2022-07-22 섬유모세포 활성화 단백질 억제제 및 그의 용도 Pending KR20240040092A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21187424.3A EP4122499A1 (en) 2021-07-23 2021-07-23 Fibroblast activation protein inhibitors and use thereof
EP21187424.3 2021-07-23
PCT/EP2022/070693 WO2023002045A1 (en) 2021-07-23 2022-07-22 Fibroblast activation protein inhibitors and use thereof

Publications (1)

Publication Number Publication Date
KR20240040092A true KR20240040092A (ko) 2024-03-27

Family

ID=77042830

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247005694A Pending KR20240040092A (ko) 2021-07-23 2022-07-22 섬유모세포 활성화 단백질 억제제 및 그의 용도

Country Status (11)

Country Link
US (1) US20240335569A1 (https=)
EP (2) EP4122499A1 (https=)
JP (1) JP2024527627A (https=)
KR (1) KR20240040092A (https=)
CN (1) CN117769443A (https=)
AU (1) AU2022313521A1 (https=)
CA (1) CA3224514A1 (https=)
CL (1) CL2024000200A1 (https=)
IL (1) IL310306A (https=)
MX (1) MX2024000866A (https=)
WO (1) WO2023002045A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475900A1 (en) 2022-02-09 2024-12-18 Novartis AG Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent
EP4342890A1 (en) * 2022-09-21 2024-03-27 Erasmus University Rotterdam Medical Center Platform and scaffold for fap targeting agents
WO2025106939A1 (en) * 2023-11-16 2025-05-22 Praxis Biotech LLC Conjugates targeting fibroblast activation protein and uses thereof
CN119604492A (zh) * 2023-12-08 2025-03-11 北京师范大学 一种放射性标记fapi配合物及其制备方法和应用
WO2025167951A1 (zh) * 2024-02-07 2025-08-14 苏州博锐创合医药有限公司 一种成纤维细胞活化蛋白抑制剂
WO2025240871A1 (en) * 2024-05-16 2025-11-20 Purdue Research Foundation Chemically stable keto-amide-based fibroblast activation protein-targeted nanoparticle-based magnetic resonance imaging agent, compositions, and methods of use
CN118978511A (zh) * 2024-08-02 2024-11-19 江苏华益科技有限公司 一种靶向fap化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
CN103370063A (zh) 2010-12-13 2013-10-23 免疫医疗公司 用于改善蛋白质、肽和其他分子的f-18标记的方法和组合物
DE102014115088A1 (de) 2014-10-16 2016-04-21 Sovicell Gmbh Bestimmung von Bindungskonstanten mittels Gleichgewichtsverlagerung
EA202090776A1 (ru) * 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
SG11202007180QA (en) * 2018-02-06 2020-08-28 Univ Heidelberg Fap inhibitor
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂

Also Published As

Publication number Publication date
IL310306A (en) 2024-03-01
AU2022313521A1 (en) 2023-12-14
CA3224514A1 (en) 2023-01-26
EP4122499A1 (en) 2023-01-25
MX2024000866A (es) 2024-02-09
WO2023002045A1 (en) 2023-01-26
EP4373529A1 (en) 2024-05-29
CN117769443A (zh) 2024-03-26
AU2022313521A9 (en) 2024-01-04
CL2024000200A1 (es) 2024-06-14
US20240335569A1 (en) 2024-10-10
JP2024527627A (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
JP7783396B2 (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US20240335569A1 (en) Fibroblast activation protein inhibitors and use thereof
US20230212549A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
US20240115745A1 (en) Compounds comprising a fibroblast activation protein ligand and use thereof
JP2026062901A (ja) 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
US20250339569A1 (en) Carbonic anhydrase ix ligands
WO2022123462A1 (en) Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
CN118591549A (zh) 碳酸酐酶ix配位体
RU2836270C2 (ru) Соединения, содержащие лиганд белка активации фибробластов, и их применение
TW202334177A (zh) 包含纖維母細胞活化蛋白配體之化合物和彼之用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000